Private equity firm Amicus Capital Partners, which closed its second fund earlier this year at $214 million after exceeding its initial target, is generating lucrative returns from a portfolio company ...

Amicus Therapeutics (FOLD) reported Q3 results that caught investors’ attention, posting GAAP profitability along with solid revenue gains from its rare disease therapies. Global expansion and ...

Courtly Observations is a recurring series by Erwin Chemerinsky that focuses on what the Supreme Court’s decisions will mean for the law, for lawyers and lower courts, and for people’s lives. Please ...

The Supreme Court is, apparently, reading its amicus briefs — and one of them may provide an offramp from immediately having to decide whether President Trump has the power to deploy the National ...

Amicus Therapeutics remains a Buy, supported by strong momentum in Galafold and Pombiliti/Opfolda, both with blockbuster potential. FOLD's Galafold leads in Fabry disease as the first oral precision ...

For years, we've all driven by the "big green round thing" — as our kids like to call it — in Downtown Tallahassee and wondered, "Is anything ever gonna go in the Old City Waterworks building? Seems ...

A recent upgrade from a Needham analyst, who has shifted Amicus Therapeutics (FOLD) to a buy rating, is drawing attention. The analyst points to an improved outlook for the company, which could ...

RICHMOND, Va. — As the case continues against two students who were suspended from a Loudoun county public school for violating Title IX, Attorney General Jason Miyares filed an amicus curiae brief in ...

Press releases are posted on Independent.com as a free community service. OAKLAND — California Attorney General Rob Bonta today led a coalition of 20 attorneys general in filing an amicus brief in ...

Amicus Therapeutics (NASDAQ:FOLD) traded higher on Thursday after Morgan Stanley upgraded the stock, citing a favorable setup for the company ahead of a key ruling in its patent dispute with generic ...

According to Cofounder and partner at Amicus Capital, Mahesh Parasuraman, the fund had exceeded its target corpus of $200 Mn The India-focussed fund was launched in March 2023 which aims to back 10-12 ...